Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 3, Issue 7, 2022

Research progress on biomarkers of cerebral small vessel disease

Download as PDF

DOI: 10.23977/medsc.2022.030712 | Downloads: 22 | Views: 670

Author(s)

Chen Ling 1, Longbin Jia 2

Affiliation(s)

1 Changzhi Medical College, Changzhi, Shanxi, 046000, China
2 Department of Neurology, Jincheng People's Hospital, Jincheng, Shanxi, 048000, China

Corresponding Author

Longbin Jia

ABSTRACT

Relevant data show that with the accelerating aging population in China, cerebral small vessel disease the diagnosis rate of Cerebral small vessel disease (CSVD) is also increasing year by year. Patients may have cognitive decline, gait disorder, mental and emotional changes, swallowing disorder, and abnormal urine and stool, which seriously affect the quality of life. At present, the pathogenesis of CSVD is still unclear. The author believes that the research on biomarkers of CSVD may have broad prospects. Therefore, this paper analyzes the inflammation-related markers of CSVD, Immune-related markers, and genetic-related markers to provide a new reference direction for early diagnosis, disease monitoring, and clinical treatment of CSVD.

KEYWORDS

Cerebral small vessel disease; Pathogenesis; Biomarkers; Neurofilament Light Chain

CITE THIS PAPER

Chen Ling, Longbin Jia, Research progress on biomarkers of cerebral small vessel disease. MEDS Clinical Medicine (2022) Vol. 3: 68-74. DOI: http://dx.doi.org/10.23977/medsc.2022.030712.

REFERENCES

[1] Wardlaw JM, Smith EE, Biessels GJ, et al: Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet Neurology 2013, 12:822-838.
[2] Zwanenburg JJM, van Osch MJP: Targeting Cerebral Small Vessel Disease With MRI. Stroke 2017, 48:3175-3182.
[3] Jokinen H, Koikkalainen J, Laakso HM, et al: Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. Stroke 2020, 51:170-178.
[4] Cannistraro RJ, Badi M, Eidelman BH,et al: CNS small vessel disease: A clinical review. Neurology 2019, 92:1146-1156.
[5] Pantoni L: Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. The Lancet Neurology 2010, 9:689-701.
[6] Wardlaw JM, Smith C, Dichgans M: Small vessel disease: mechanisms and clinical implications. The Lancet Neurology 2019, 18:684-696.
[7] Hu Wenli, Yang Lei, Li Ting, Huang Yonghua. Expert consensus on the diagnosis and treatment of small cerebral blood vessel diseases in China 2021 [J]. Chinese Journal of Stroke, 2021,16 (07): 716-726.
[8] Li T, Huang Y, Cai W, et al: Age-related cerebral small vessel disease and inflammaging. Cell Death Dis 2020, 11:932.
[9] Cai W, Chen X, Men X, et al: Gut microbiota from patients with arteriosclerotic CSVD induces higher IL-17A production in neutrophils via activating RORγt. Science advances 2021, 7.
[10] Jalal FY, Yang Y, Thompson JF, et al: Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP. J Cereb Blood Flow Metab 2015, 35:1145-1153.
[11] Joutel A, Corpechot C, Ducros A, et al: Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996, 383:707-710.
[12] Mishra A, Chauhan G, Violleau MH, et al: Association of variants in HTRA1 and NOTCH3 with MRI-defined extremes of cerebral small vessel disease in older subjects. Brain 2019, 142:1009-1023.
[13] Rannikmäe K, Davies G, Thomson PA, et al: Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. Neurology 2015, 84:918-926.
[14] Giau VV, Bagyinszky E, Youn YC,et al: Genetic Factors of Cerebral Small Vessel Disease and Their Potential Clinical Outcome. Int J Mol Sci 2019, 20.
[15] Miyatake S, Schneeberger S, Koyama N,et al: Biallelic COLGALT1 variants are associated with cerebral small vessel disease. Annals of neurology 2018, 84:843-853.
[16] Low A, Mak E, Rowe JB, et al: Inflammation and cerebral small vessel disease: A systematic review. Ageing Res Rev 2019, 53:100916.
[17] Shoamanesh A, Preis SR, Beiser AS, et al: Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology 2015, 84:825-832.
[18] Gregory MA, Manuel-Apolinar L, Sánchez-Garcia S, et al: Soluble Intercellular Adhesion Molecule-1 (sICAM-1) as a Biomarker of Vascular Cognitive Impairment in Older Adults. Dementia and geriatric cognitive disorders 2019, 47:243-253.
[19] Ma C, Yang L, Wang L: Correlation of Serum C-Peptide, Soluble Intercellular Adhesion Molecule-1, and NLRP3 Inflammasome-Related Inflammatory Factor Interleukin-1β after Brain Magnetic Resonance Imaging Examination with Cerebral Small Vessel Disease. Contrast media & molecular imaging 2022, 2022:4379847.
[20] Saadi M, Karkhah A, Pourabdolhossein F, et al:  Involvement of nlrc4 inflammasome through caspase-1 and IL-1β augments neuroinflammation and contributes to memory impairment in an experimental model of Alzheimer's like disease. Brain research bulletin 2020, 154:81-90.
[21] Li S, Li G, Luo X, et al: Endothelial Dysfunction and Hyperhomocysteinemia-Linked Cerebral Small Vessel Disease: Underlying Mechanisms and Treatment Timing. Front Neurol 2021, 12:736309.
[22] Cao L, Guo Y, Zhu ZJTIjon: Effects of hyperhomocysteinemia on ischemic cerebral small vessel disease and analysis of inflammatory mechanisms. 2021, 131:362-369.
[23] Zhang X, Meng H, Blaivas M, et al: Von Willebrand Factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. 2012, 3:138-145.
[24] Love S, Miners JS: Small vessel disease, neurovascular regulation and cognitive impairment: post-mortem studies reveal a complex relationship, still poorly understood. Clin Sci (Lond) 2017, 131:1579-1589.
[25] Sun W, Luo Y, Zhang S, et al: The Relationship Between ADAMTS13 Activity and Overall Cerebral Small Vessel Disease Burden: A Cross-Sectional Study Based on CSVD. Front Aging Neurosci 2021, 13:738359.
[26] Wada M, Nagasawa H, Kurita K, et al: Cerebral small vessel disease and C-reactive protein: results of a cross-sectional study in community-based Japanese elderly. J Neurol Sci 2008, 264:43-49.
[27] Staszewski J, Skrobowska E, Piusińska-Macoch R, et al: IL-1α and IL-6 predict vascular events or death in patients with cerebral small vessel disease-Data from the SHEF-CSVD study. 2019, 64:258-266.
[28] Liu N, Liu J-T, Ji Y-Y, et al: C-reactive protein triggers inflammatory responses partly via TLR4/IRF3/NF-κB signaling pathway in rat vascular smooth muscle cells. Life Sciences 2010, 87:367-374.
[29] Walker KA, Windham BG, Power MC, et al: The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study. Neurobiol Aging 2018, 68:26-33.
[30] Hainsworth AH, Minett T, Andoh J, et al: Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia. Stroke 2017, 48:2799-2804.
[31] Guo X, Deng B, Zhong L, et al: Fibrinogen is an Independent Risk Factor for White Matter Hyperintensities in CADASIL but not in Sporadic Cerebral Small Vessel Disease Patients. 2021, 12:801-811.
[32] Huang X, Zhang J, Liu J, Sun L, et al: C-reactive protein promotes adhesion of monocytes to endothelial cells via NADPH oxidase-mediated oxidative stress. Journal of cellular biochemistry 2012, 113:857-867.
[33] Noz MP, Ter Telgte A, Wiegertjes K,et al: Trained Immunity Characteristics Are Associated With Progressive Cerebral Small Vessel Disease. Stroke 2018, 49:2910-2917.
[34] Noz MP, Ter Telgte A, Wiegertjes K, et al: Pro-inflammatory Monocyte Phenotype During Acute Progression of Cerebral Small Vessel Disease. Frontiers in cardiovascular medicine 2021, 8:639361.
[35] Fu Y, Yan Y: Emerging Role of Immunity in Cerebral Small Vessel Disease. Front Immunol 2018, 9:67.
[36] Kaiser D, Weise G, Moller K, et al: Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: an animal model of early-stage cerebral small vessel disease. Acta Neuropathol Commun 2014, 2:169.
[37] Lou N, Takano T, Pei Y, et al: Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proceedings of the National Academy of Sciences of the United States of America 2016, 113:1074-1079.
[38] Koizumi T, Kerkhofs D, Mizuno T, et al: Vessel-Associated Immune Cells in Cerebrovascular Diseases: From Perivascular Macrophages to Vessel-Associated Microglia. Front Neurosci 2019, 13:1291.
[39] Pedragosa J, Salas-Perdomo A, Gallizioli M, et al: CNS-border associated macrophages respond to acute ischemic stroke attracting granulocytes and promoting vascular leakage. Acta Neuropathol Commun 2018, 6:76.
[40] Xue F, Du H: TREM2 Mediates Microglial Anti-Inflammatory Activations in Alzheimer's Disease: Lessons Learned from Transcriptomics. Cells 2021, 10.
[41] Bekris LM, Khrestian M, Dyne E, et al: Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease. Journal of neuroimmunology 2018, 319:19-27.
[42] Tsai HH, Chen YF, Yen RF,et al: Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau. Brain 2021, 144:3371-3380.
[43] Zheng Jinping, Xie Le, Fang Rui, Zhou Yue, Xie Yao, Ge Jinwen, Wu Dahua. Progress in biomarkers of cerebral small vessel disease [J]. World Science and Technology- -Modernization of Traditional Chinese Medicine, 2021,23 (12): 4398-4405.
[44] Larsson C, Lardelli M, White I, et al: The human NOTCH1, 2, and 3 genes are located at chromosome positions 9q34, 1p13-p11, and 19p13.2-p13.1 in regions of neoplasia-associated translocation. Genomics 1994, 24:253-258.
[45] Di Donato I, Bianchi S, De Stefano N, et al: Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) as a model of small vessel disease: update on clinical, diagnostic, and management aspects. BMC Med 2017, 15:41.
[46] Joutel A, Monet-Leprêtre M, Gosele C, et al: Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. The Journal of clinical investigation 2010, 120:433-445.
[47] Rannikmäe K, Henshall DE, Thrippleton S, et al: Beyond the Brain: Systematic Review of Extracerebral Phenotypes Associated With Monogenic Cerebral Small Vessel Disease. Stroke 2020, 51:3007-3017.
[48] Pelzer N, Hoogeveen ES, Haan J, et al: Systemic features of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a monogenic small vessel disease. J Intern Med 2019, 285:317-332.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4653
Visits: 203496

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.